Recent Study: Morocco Pharmaceuticals & Healthcare Report Q3 2014

Despite the Moroccan government announcing a new economic policy prioritising the innovative biopharmaceutical industry as a strategic sector within the economy, unclear policy formation processes and underdeveloped institutions will continue to cloud the country's pharmaceutical investment outlook in the medium - to - long term. An unstable and inefficient regulatory environment works to create a tough operating environment for drugmakers - particularly challenging in a market also characterised by demand side issues such as low health insurance coverage and weak healthcare infrastructure.

Headline Expenditure Projections

Full Report Details at
- http://www.fastmr.com/prod/850890_morocco_pharmaceuticals_healthcare_report_q3_2014.aspx?afid=301

* Pharmaceuticals: MAD9.32bn (USD1.11bn) in 2013 to MAD9.58bn (USD1.15bn) in 2014; +2.8% in local currency terms and +3.1% in US dollar terms.
* Healthcare: MAD57.96bn (USD6.90bn) in 2013 to MAD63.26bn (USD7.56bn) in 2014; +9.1% in local currency terms and +9.5% in US dollar terms. Forecast higher than in Q 214 due to upward revision of historical figures for pharmaceutical market.

Risk/Reward Rating

In our latest proprietary Pharmaceutical Risk/Reward Ratings (RRR), Morocco continues to be viewed as a moderately attractive pharmaceutical market in the Middle East and Africa (MEA) region, from a longer-term perspective. Morocco ranks 15 ^th in the region, out of the 30 countries assessed in our ratings matrix, with a score of 42.3 out of 100. The market's constraints include low per capita consumption and an underdeveloped reimbursement system, although such factors are to a degree offset by a relatively predictable operating environment.

Key Trends And Developments

June

More than 60mn medicines will be sold at reduced prices in Morocco from June 9, reports almaghribia.ma. The government lowered the prices of medicines belonging to 989 medical specialties by 20-80%. The government has focused particularly on decreasing the prices of medicines used in the treatment of various heart diseases, metabolic diseases and cancerous...

The Morocco Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Morocco Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Moroccan pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Morocco to test other views - a key input for successful budgeting and strategic business planning in the Moroccan pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Egypt Pharmaceuticals & Healthcare Report Q3 2014
- Moldova Pharmaceuticals & Healthcare Report Q3 2014
- Peru Pharmaceuticals & Healthcare Report Q3 2014
- France Pharmaceuticals & Healthcare Report Q3 2014
- Turkey Pharmaceuticals & Healthcare Report Q3 2014